Compare Stocks: ADAP, CTOR, XLO, and PMVP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
CTOR Citius Oncology	$0.79 -2.8%	$0.69	$0.49 ▼ $2.25	$73.19M	3.48	167,176 shs	16,986 shs
PMVP PMV Pharmaceuticals	$1.31 +0.4%	$1.23	$1.02 ▼ $1.88	$70.03M	1.34	440,753 shs	94,454 shs
XLO Xilio Therapeutics	$9.05 -0.3%	$9.08	$6.47 ▼ $12.74	$59.55M	-0.14	38,931 shs	7,709 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-5.08%
CTOR Citius Oncology	+8.01%	+15.23%	+44.09%	-8.86%	-57.14%
PMVP PMV Pharmaceuticals	0.00%	+5.24%	+5.24%	+8.75%	-8.10%
XLO Xilio Therapeutics	-1.20%	-4.42%	+4.97%	+8.87%	-7.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -10.5%	$0.09	$0.04 ▼ $0.36	$15.35M	2.49	57.14 million shs	49.26 million shs
CTOR Citius Oncology	$0.79 -2.8%	$0.69	$0.49 ▼ $2.25	$73.19M	3.48	167,176 shs	16,986 shs
PMVP PMV Pharmaceuticals	$1.31 +0.4%	$1.23	$1.02 ▼ $1.88	$70.03M	1.34	440,753 shs	94,454 shs
XLO Xilio Therapeutics	$9.05 -0.3%	$9.08	$6.47 ▼ $12.74	$59.55M	-0.14	38,931 shs	7,709 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	0.00%	0.00%	0.00%	-5.08%
CTOR Citius Oncology	+8.01%	+15.23%	+44.09%	-8.86%	-57.14%
PMVP PMV Pharmaceuticals	0.00%	+5.24%	+5.24%	+8.75%	-8.10%
XLO Xilio Therapeutics	-1.20%	-4.42%	+4.97%	+8.87%	-7.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	1.00	Sell	N/A	N/A
CTOR Citius Oncology	2.33	Hold	$6.00	662.29% Upside
PMVP PMV Pharmaceuticals	2.75	Moderate Buy	$4.00	205.34% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ADAP, CTOR, XLO, and PMVP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	PMVP PMV Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.00
7/1/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/30/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/23/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.09	N/A	N/A	$0.05 per share	1.16
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.43 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.34 per share	N/A
XLO Xilio Therapeutics	$43.77M	1.36	N/A	N/A	$10.98 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	N/A
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest ADAP, CTOR, XLO, and PMVP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	N/A	1.52	1.29
CTOR Citius Oncology	0.25	0.73	0.34
PMVP PMV Pharmaceuticals	N/A	7.70	7.70
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CTOR Citius Oncology	70.52%
PMVP PMV Pharmaceuticals	90.20%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
CTOR Citius Oncology	9.80%
PMVP PMV Pharmaceuticals	10.15%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.87 million	N/A
PMVP PMV Pharmaceuticals	50	53.46 million	48.03 million	Optionable
XLO Xilio Therapeutics	70	6.58 million	6.09 million	Not Optionable

ADAP, CTOR, XLO, and PMVP Headlines

Recent News About These Companies

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 58.8% in July

August 18, 2026 | americanbankingnews.com

Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8%

August 18, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

August 12, 2026 | marketbeat.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Trading Down 0.2% - Here's Why

July 31, 2026 | marketbeat.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2026 | globenewswire.com

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

April 1, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADAP, CTOR, XLO, and PMVP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Citius Oncology NASDAQ:CTOR

$0.79 -0.02 (-2.84%)

As of 04:00 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

PMV Pharmaceuticals NASDAQ:PMVP

$1.31 +0.01 (+0.38%)

As of 04:00 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Xilio Therapeutics NASDAQ:XLO

$9.05 -0.03 (-0.33%)

As of 03:59 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, CTOR, XLO, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, CTOR, XLO, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, CTOR, XLO, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAP, CTOR, XLO, and PMVP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Citius Oncology NASDAQ:CTOR

PMV Pharmaceuticals NASDAQ:PMVP

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADAP, CTOR, XLO, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADAP, CTOR, XLO, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADAP, CTOR, XLO, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADAP, CTOR, XLO, and PMVP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

Citius Oncology NASDAQ:CTOR

PMV Pharmaceuticals NASDAQ:PMVP

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools